- Home
- INKT
as 05-09-2025 4:00pm EST
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
Upcoming Earnings Alert:
Get ready for potential market movements as MiNK Therapeutics Inc. INKT prepares to release earnings report on 15 May 2025.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 31.2M | IPO Year: | 2021 |
| Target Price: | $37.50 | AVG Volume (30 days): | 2.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.86 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.56 - $13.79 | Next Earning Date: | 05-15-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest MiNK Therapeutics Inc. News
INKT Breaking Stock News: Dive into INKT Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report
GuruFocus.com
2 months ago
MiNK Therapeutics Inc (INKT) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ...
Thomson Reuters StreetEvents
2 months ago
Q4 2024 Mink Therapeutics Inc Earnings Call
GlobeNewswire
2 months ago
MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress
Simply Wall St.
2 months ago
Are MiNK Therapeutics, Inc. (NASDAQ:INKT) Investors Paying Above The Intrinsic Value?
GlobeNewswire
2 months ago
MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report
GlobeNewswire
3 months ago
MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting
GlobeNewswire
3 months ago
MiNK Therapeutics Regains Full Compliance with Nasdaq Listing Requirements
Compare INKT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INKT MiNK Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.